Table 3 Displays the change in the assessed imaging features between the first and second PET/MRI examination, for both chemotherapy responders and non-responders. Absolute values from the baseline as well as the follow-up PET/MRI can be found in the supplementary material (A. 2)
From: [18F]FDG PET/MRI enables early chemotherapy response prediction in pancreatic ductal adenocarcinoma
|  | Responder (Mean ± SD) | Non-responder (Mean ± SD | p-value |
|---|---|---|---|
∆MTV50% | −0.28 ± 0.18 |  + 1.26 ± 0.98 |  < 0.0001 |
∆ADCmean |  + 0.27 ± 0.10 |  + 0.07 ± 0.09 | 0.0011 |
∆TLG50% | −0.39 ± 0.14 |  + 0.63 ± 1.12 | 0.0054 |
∆SUVmax | −0.24 ± 0.17 | −0.33 ± 0.18 | 0.3372 |
∆SUVpeak | −0.15 ± 0.13 | −1.23 ± 0.25 | 0.8296 |
∆MTV2,5 | −0.53 ± 0.24 |  + 0.05 ± 0.98 | 0.0696 |
∆TLG2,5 | −0.53 ± 0.26 | −0.02 ± 1.1 | 0.1419 |
∆ADCmin |  + 0.33 ± 0.26 | −0.07 ± 0.21 | 0.0080 |
∆ADCmax | 0.24 ± 0.16 | 0.26 ± 0.14 | 0.7955 |